Shenzhen Shares Suffer Worst Week Since December 1996

Related Link: 

China shares tumbled Friday, even as Beijing moves swiftly to try to plug losses, with the smaller Shenzhen index suffering its worst week since December 1996.

Investors on Edge Ahead of Greek Referendum

Related Link: 

With opinion polls suggesting the vote on Greek austerity may be close, many investors are opting to ride out the storm and stick with their holdings of European stocks.

Aetna to Buy Humana for $37 Billion

Related Link: 

Aetna said it would buy Humana for $37 billion, following weeks of frenzied merger talks among large health insurers.

Germany's K+S Rebuffs Potash Takeover

Related Link: 

German salt and fertilizer company K+S AG rejected a takeover approach worth $8.75 billion by rival Potash Corp. of Saskatchewan, saying the proposal undervalued the company.

Airlines' New Normal: More Seats, Fewer Flights

Related Link: 

Using an industry technique known as “upgauging,” airlines increase capacity by adding seats on existing jets and replacing smaller planes with larger ones.

Investigators Believe Funds Flowed to Malaysian Leader's Accounts

Related Link: 

Malaysian investigators scrutinizing a government investment fund have traced nearly $700 million of deposits into what they believe are the personal bank accounts of Prime Minister Najib Razak, according to documents from a government probe.

BP to Pay $18.7 Billion to Settle Deepwater Horizon Spill Claims

Related Link: 

BP agreed to pay $18.7 billion over 18 years to settle all federal and state claims arising from 2010’s Deepwater Horizon oil spill, including the biggest pollution penalty in U.S. history.

Europe's Crowning Glory Imperils Postwar Project

Related Link: 

The great project some hoped would eventually create a European superstate faces the biggest challenge of its history Sunday, when Greeks vote in a referendum that could decide whether they crash out of the eurozone.

Vertex's $259,000 Cystic Fibrosis Drug Approved

Related Link: 

Vertex’s cystic-fibrosis drug Orkambi, which treats the most common mutation of the disease, received U.S. regulatory approval on Thursday.

AIG a Wallflower at Insurer-Merger Dance

Related Link: 

The acquisition of Chubb by ACE likely signals the start of a merger rush for U.S. insurers. AIG isn’t likely to join in.

Syndicate content